We are analyzing https://link.springer.com/article/10.1007/s10549-008-9924-5.

Title:
TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype | Breast Cancer Research and Treatment
Description:
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in some but not all breast cancer cell lines. Breast cancers can be divided into those which express the estrogen (ER) and progesterone (PR) receptors, those with HER-2 amplification, and those without expression of ER, PR, or HER-2 amplification (referred to as basal or triple-negative breast cancer). We tested a panel of 20 breast cancer cell lines representing the different types of breast cancer to evaluate if the molecular phenotype of the breast cancer cells determined their response to TRAIL. The most striking finding was that eight of eleven triple-negative cell lines are sensitive to TRAIL-mediated apoptosis. The eight TRAIL-sensitive triple-negative cell lines have a mesenchymal phenotype while the three TRAIL-resistant triple-negative cell lines have an epithelial phenotype. Two of five cell lines with HER-2 amplification were sensitive to TRAIL and none of the five ER positive cell lines were sensitive. RNAi-mediated knockdown of TRAIL receptor expression demonstrated that TRAIL Receptor 2 (TRAIL-R2) mediates the effects of TRAIL, even when both TRAIL-R1 and TRAIL-R2 are expressed. Finally, inhibition of EGFR, expressed in both TRAIL-sensitive and TRAIL-resistant triple-negative breast cancer cell lines, using a small molecule tyrosine kinase inhibitor (AG1478), enhanced TRAIL-induced apoptosis in TRAIL-sensitive cell lines but did not convert resistant cells into TRAIL-sensitive cells. Together, these findings suggest that a subset of triple-negative breast cancer, those with mesenchymal features, may be the most likely to benefit from TRAIL targeted therapy. These findings could form the basis to select breast cancer patients for clinical trials of TRAIL-R2 ligands.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

cancer, breast, article, google, scholar, pubmed, cas, cell, lines, trail, apoptosis, expression, res, cells, tumor, receptor, research, triplenegative, apoptosisinducing, gene, necrosis, ligand, growth, factorrelated, factor, usa, biol, human, privacy, cookies, content, data, phenotype, lipkowitz, amplification, molecular, trailr, egfr, access, epidermal, information, publish, search, mesenchymal, davis, pumphrey, nau, basal, sensitive, trailsensitive,

Topics {✒️}

related apoptosis-inducing ligand inhibitor-enhanced trail-induced apoptosis triple-negative breast cancer tumour-necrosis factor superfamily enhanced trail-induced apoptosis month download article/chapter proapoptotic ligand apo2l/trail epidermal growth factor trail-mediated apoptosis trail-sensitive cell lines convert resistant cells breast tumor heterogeneity fas-induced apoptosis estrogen receptor-negative keane mm breast cell lines trail induces apoptosis open software development basal breast carcinomas trail-sensitive cells breast cancer therapy sum-159pt cells receptor-selective mutants drug development phenotypic evaluation invasive breast carcinoma full article pdf rnai-mediated knockdown privacy choices/manage cookies defining trail sensitivity national cancer institute induces apoptosis related subjects epithelial-mesenchymal transition breast cancer selectively inhibits growth check access intramural research program instant access trail targeted therapy cancer cell 10 cancer cell 11 cell lines tyrosine kinase inhibition primary lymphoid malignancies tumor formation trail-r2 ligands apoptosis signaling article rahman official gene symbol

Questions {❓}

Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype
         description:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in some but not all breast cancer cell lines. Breast cancers can be divided into those which express the estrogen (ER) and progesterone (PR) receptors, those with HER-2 amplification, and those without expression of ER, PR, or HER-2 amplification (referred to as basal or triple-negative breast cancer). We tested a panel of 20 breast cancer cell lines representing the different types of breast cancer to evaluate if the molecular phenotype of the breast cancer cells determined their response to TRAIL. The most striking finding was that eight of eleven triple-negative cell lines are sensitive to TRAIL-mediated apoptosis. The eight TRAIL-sensitive triple-negative cell lines have a mesenchymal phenotype while the three TRAIL-resistant triple-negative cell lines have an epithelial phenotype. Two of five cell lines with HER-2 amplification were sensitive to TRAIL and none of the five ER positive cell lines were sensitive. RNAi-mediated knockdown of TRAIL receptor expression demonstrated that TRAIL Receptor 2 (TRAIL-R2) mediates the effects of TRAIL, even when both TRAIL-R1 and TRAIL-R2 are expressed. Finally, inhibition of EGFR, expressed in both TRAIL-sensitive and TRAIL-resistant triple-negative breast cancer cell lines, using a small molecule tyrosine kinase inhibitor (AG1478), enhanced TRAIL-induced apoptosis in TRAIL-sensitive cell lines but did not convert resistant cells into TRAIL-sensitive cells. Together, these findings suggest that a subset of triple-negative breast cancer, those with mesenchymal features, may be the most likely to benefit from TRAIL targeted therapy. These findings could form the basis to select breast cancer patients for clinical trials of TRAIL-R2 ligands.
         datePublished:2008-02-12T00:00:00Z
         dateModified:2008-02-12T00:00:00Z
         pageStart:217
         pageEnd:230
         sameAs:https://doi.org/10.1007/s10549-008-9924-5
         keywords:
            TRAIL
            Apoptosis
            Basal breast cancer
            Triple-negative breast cancer
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-9924-5/MediaObjects/10549_2008_9924_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-9924-5/MediaObjects/10549_2008_9924_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-9924-5/MediaObjects/10549_2008_9924_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-9924-5/MediaObjects/10549_2008_9924_Fig4a_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-9924-5/MediaObjects/10549_2008_9924_Fig4b_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-9924-5/MediaObjects/10549_2008_9924_Fig5_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:113
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Monzur Rahman
               affiliation:
                     name:National Cancer Institute, NIH
                     address:
                        name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sean R. Davis
               affiliation:
                     name:National Cancer Institute, NIH
                     address:
                        name:Genetics Department, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Janet G. Pumphrey
               affiliation:
                     name:National Cancer Institute, NIH
                     address:
                        name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jing Bao
               affiliation:
                     name:National Cancer Institute, NIH
                     address:
                        name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marion M. Nau
               affiliation:
                     name:National Cancer Institute, NIH
                     address:
                        name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Paul S. Meltzer
               affiliation:
                     name:National Cancer Institute, NIH
                     address:
                        name:Genetics Department, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stanley Lipkowitz
               affiliation:
                     name:National Cancer Institute, NIH
                     address:
                        name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype
      description:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in some but not all breast cancer cell lines. Breast cancers can be divided into those which express the estrogen (ER) and progesterone (PR) receptors, those with HER-2 amplification, and those without expression of ER, PR, or HER-2 amplification (referred to as basal or triple-negative breast cancer). We tested a panel of 20 breast cancer cell lines representing the different types of breast cancer to evaluate if the molecular phenotype of the breast cancer cells determined their response to TRAIL. The most striking finding was that eight of eleven triple-negative cell lines are sensitive to TRAIL-mediated apoptosis. The eight TRAIL-sensitive triple-negative cell lines have a mesenchymal phenotype while the three TRAIL-resistant triple-negative cell lines have an epithelial phenotype. Two of five cell lines with HER-2 amplification were sensitive to TRAIL and none of the five ER positive cell lines were sensitive. RNAi-mediated knockdown of TRAIL receptor expression demonstrated that TRAIL Receptor 2 (TRAIL-R2) mediates the effects of TRAIL, even when both TRAIL-R1 and TRAIL-R2 are expressed. Finally, inhibition of EGFR, expressed in both TRAIL-sensitive and TRAIL-resistant triple-negative breast cancer cell lines, using a small molecule tyrosine kinase inhibitor (AG1478), enhanced TRAIL-induced apoptosis in TRAIL-sensitive cell lines but did not convert resistant cells into TRAIL-sensitive cells. Together, these findings suggest that a subset of triple-negative breast cancer, those with mesenchymal features, may be the most likely to benefit from TRAIL targeted therapy. These findings could form the basis to select breast cancer patients for clinical trials of TRAIL-R2 ligands.
      datePublished:2008-02-12T00:00:00Z
      dateModified:2008-02-12T00:00:00Z
      pageStart:217
      pageEnd:230
      sameAs:https://doi.org/10.1007/s10549-008-9924-5
      keywords:
         TRAIL
         Apoptosis
         Basal breast cancer
         Triple-negative breast cancer
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-9924-5/MediaObjects/10549_2008_9924_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-9924-5/MediaObjects/10549_2008_9924_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-9924-5/MediaObjects/10549_2008_9924_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-9924-5/MediaObjects/10549_2008_9924_Fig4a_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-9924-5/MediaObjects/10549_2008_9924_Fig4b_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-9924-5/MediaObjects/10549_2008_9924_Fig5_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:113
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Monzur Rahman
            affiliation:
                  name:National Cancer Institute, NIH
                  address:
                     name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sean R. Davis
            affiliation:
                  name:National Cancer Institute, NIH
                  address:
                     name:Genetics Department, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Janet G. Pumphrey
            affiliation:
                  name:National Cancer Institute, NIH
                  address:
                     name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jing Bao
            affiliation:
                  name:National Cancer Institute, NIH
                  address:
                     name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marion M. Nau
            affiliation:
                  name:National Cancer Institute, NIH
                  address:
                     name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Paul S. Meltzer
            affiliation:
                  name:National Cancer Institute, NIH
                  address:
                     name:Genetics Department, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stanley Lipkowitz
            affiliation:
                  name:National Cancer Institute, NIH
                  address:
                     name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:113
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:National Cancer Institute, NIH
      address:
         name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
         type:PostalAddress
      name:National Cancer Institute, NIH
      address:
         name:Genetics Department, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
         type:PostalAddress
      name:National Cancer Institute, NIH
      address:
         name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
         type:PostalAddress
      name:National Cancer Institute, NIH
      address:
         name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
         type:PostalAddress
      name:National Cancer Institute, NIH
      address:
         name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
         type:PostalAddress
      name:National Cancer Institute, NIH
      address:
         name:Genetics Department, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
         type:PostalAddress
      name:National Cancer Institute, NIH
      address:
         name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Monzur Rahman
      affiliation:
            name:National Cancer Institute, NIH
            address:
               name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
               type:PostalAddress
            type:Organization
      name:Sean R. Davis
      affiliation:
            name:National Cancer Institute, NIH
            address:
               name:Genetics Department, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
               type:PostalAddress
            type:Organization
      name:Janet G. Pumphrey
      affiliation:
            name:National Cancer Institute, NIH
            address:
               name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
               type:PostalAddress
            type:Organization
      name:Jing Bao
      affiliation:
            name:National Cancer Institute, NIH
            address:
               name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
               type:PostalAddress
            type:Organization
      name:Marion M. Nau
      affiliation:
            name:National Cancer Institute, NIH
            address:
               name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
               type:PostalAddress
            type:Organization
      name:Paul S. Meltzer
      affiliation:
            name:National Cancer Institute, NIH
            address:
               name:Genetics Department, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
               type:PostalAddress
            type:Organization
      name:Stanley Lipkowitz
      affiliation:
            name:National Cancer Institute, NIH
            address:
               name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
      name:Genetics Department, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
      name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
      name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
      name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
      name:Genetics Department, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
      name:Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(131)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.14s.

LINK . SPRINGER . COM {}